share_log

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Short Interest Update

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Short Interest Update

芬奇治疗集团(纳斯达克市场代码：FNCH)空头股数更新
kopsource ·  2022/08/03 12:41

Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Rating) was the target of a significant drop in short interest in the month of July. As of July 15th, there was short interest totalling 285,900 shares, a drop of 24.5% from the June 30th total of 378,600 shares. Based on an average daily volume of 968,000 shares, the short-interest ratio is currently 0.3 days. Currently, 1.9% of the shares of the company are sold short.

芬奇治疗集团公司(纳斯达克代码：FNCH-GET评级)是空头股数7月份大幅下降的目标。截至7月15日，空头股数共有28.59万股，较6月30日的37.86万股下降了24.5%。以日均成交量9.68,000股计算，短息比率目前为0.3天。目前，该公司1.9%的股份被卖空。

Finch Therapeutics Group Stock Performance

芬奇治疗集团股票表现

Finch Therapeutics Group stock traded up $0.17 during midday trading on Wednesday, reaching $2.07. 5 shares of the company's stock were exchanged, compared to its average volume of 39,337. Finch Therapeutics Group has a 52 week low of $1.71 and a 52 week high of $17.39. The firm has a market cap of $98.45 million, a price-to-earnings ratio of -1.43 and a beta of -0.52. The stock's 50-day simple moving average is $2.44 and its 200 day simple moving average is $4.50.

芬奇治疗集团的股票在周三午盘交易中上涨0.17美元，达到2.07美元。该公司股票的交易量为5股，而其平均成交量为39,337股。芬奇治疗集团的52周低点为1.71美元，52周高点为17.39美元。该公司市值为9845万美元，市盈率为-1.43，贝塔系数为-0.52。该股的50日简单移动均线切入位在2.44美元，200日简单移动均线切入位在4.50美元。

Get
到达
Finch Therapeutics Group
芬奇治疗集团
alerts:
警报：

Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) last posted its quarterly earnings results on Monday, May 16th. The company reported ($0.52) EPS for the quarter. The business had revenue of $0.35 million for the quarter. Finch Therapeutics Group had a negative return on equity of 33.13% and a negative net margin of 448.35%. Research analysts forecast that Finch Therapeutics Group will post -1.98 earnings per share for the current year.

芬奇治疗集团(纳斯达克代码：FNCH-GET Rating)最近一次公布季度收益是在5月16日星期一。该公司公布了该季度每股收益(0.52美元)。该业务本季度的收入为35万美元。芬奇治疗集团的净资产回报率为负33.13%，净利润率为负448.35%。研究分析师预测，芬奇治疗集团本年度每股收益将达到1.98美元。

Institutional Investors Weigh In On Finch Therapeutics Group

机构投资者看好芬奇治疗集团

Several hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its position in Finch Therapeutics Group by 19.4% during the first quarter. Renaissance Technologies LLC now owns 45,000 shares of the company's stock worth $226,000 after acquiring an additional 7,314 shares during the last quarter. BlackRock Inc. lifted its position in Finch Therapeutics Group by 2.3% during the first quarter. BlackRock Inc. now owns 404,931 shares of the company's stock worth $2,038,000 after acquiring an additional 9,149 shares during the last quarter. Qube Research & Technologies Ltd lifted its position in Finch Therapeutics Group by 53.6% during the first quarter. Qube Research & Technologies Ltd now owns 37,631 shares of the company's stock worth $189,000 after acquiring an additional 13,128 shares during the last quarter. Light Street Capital Management LLC lifted its position in Finch Therapeutics Group by 1.8% during the fourth quarter. Light Street Capital Management LLC now owns 811,731 shares of the company's stock worth $8,093,000 after acquiring an additional 14,400 shares during the last quarter. Finally, SCS Capital Management LLC acquired a new stake in Finch Therapeutics Group during the fourth quarter worth approximately $382,000. 22.68% of the stock is currently owned by institutional investors and hedge funds.
几家对冲基金最近买卖了该股的股票。文艺复兴技术公司在第一季度将其在芬奇治疗集团的地位提高了19.4%。复兴科技有限责任公司在上个季度增持了7,314股后，现在拥有45,000股该公司股票，价值226,000美元。贝莱德股份有限公司在第一季度将其在芬奇治疗集团的头寸提高了2.3%。贝莱德股份有限公司在上个季度增持了9,149股后，目前持有404,931股该公司股票，价值2,038,000美元。Qube Research&Technologies Ltd在第一季度将其在Finch治疗集团的地位提高了53.6%。Qube Research&Technologies Ltd在上个季度额外收购了13,128股后，现在拥有37,631股该公司股票，价值18.9万美元。Light Street Capital Management LLC在第四季度将其在芬奇治疗集团的头寸提高了1.8%。Light Street Capital Management LLC现在拥有811,731股该公司的股票，价值8,093,000美元，在上个季度又收购了14,400股。最后，SCS资本管理有限责任公司在第四季度收购了芬奇治疗集团价值约38.2万美元的新股份。22.68%的股票目前由机构投资者和对冲基金持有。

About Finch Therapeutics Group

芬奇治疗集团简介

(Get Rating)

(获取评级)

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.

芬奇治疗集团公司是一家临床阶段的微生物组治疗公司，在美国开发一种新型的口服生物药物。该公司的主要候选药物是CP101，这是一种口服微生物胶囊，正处于第三阶段临床试验，用于治疗反复发作的艰难梭菌感染患者，以及治疗慢性乙肝病毒。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Finch Therapeutics Group (FNCH)
  • Is Starbucks Shooting For The Moon?
  • PayPal Continues To Struggle As Competition Increases
  • Two High-Yield Deep-Values You Shouldn't Ignore
  • Proposed Tesla Stock Split Drives EV Market Higher
  • Caterpillar Falls To Strong Support Near Bottom Of Range
  • 免费获取StockNews.com关于芬奇治疗集团(FNCH)的研究报告
  • 星巴克是在向月球进军吗？
  • PayPal继续挣扎，竞争加剧
  • 你不应该忽视的两个高收益深度价值
  • 拟议的特斯拉股票拆分推动电动汽车市场走高
  • 卡特彼勒跌至接近区间底部的强劲支撑

Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.

接受芬奇治疗集团每日新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收芬奇治疗集团和相关公司的最新新闻和分析师评级的每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发